Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,870,223
  • Shares Outstanding, K 79,775
  • Annual Sales, $ 540,100 K
  • Annual Income, $ -554,130 K
  • 60-Month Beta 1.45
  • Price/Sales 12.70
  • Price/Cash Flow N/A
  • Price/Book 12.92
Trade SRPT with:

Options Overview

Details
  • Implied Volatility 51.62%
  • Historical Volatility 58.10%
  • IV Percentile 14%
  • IV Rank 3.75%
  • IV High 175.91% on 01/05/21
  • IV Low 46.78% on 08/17/20
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,193
  • Volume Avg (30-Day) 1,733
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 63,094
  • Open Int (30-Day) 64,368

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -1.03
  • Number of Estimates 5
  • High Estimate -0.48
  • Low Estimate -1.69
  • Prior Year -1.93
  • Growth Rate Est. (year over year) +46.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.21 +15.14%
on 06/04/21
90.00 -7.62%
on 06/15/21
+7.09 (+9.32%)
since 05/14/21
3-Month
67.68 +22.84%
on 05/11/21
90.00 -7.62%
on 06/15/21
-2.80 (-3.26%)
since 03/15/21
52-Week
67.68 +22.84%
on 05/11/21
181.83 -54.28%
on 12/22/20
-74.88 (-47.39%)
since 06/15/20

Most Recent Stories

More News
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW

DVAX : 8.89 (-1.44%)
IONS : 36.68 (-2.94%)
JAZZ : 183.41 (-1.61%)
MRK : 75.70 (+0.33%)
MGEN : 23.01 (-0.09%)
SRPT : 83.14 (-3.46%)
Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPT : 83.14 (-3.46%)
Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor...

SRPT : 83.14 (-3.46%)
Global $14.1 Billion Oligonucleotide Synthesis Market to 2026 Featuring Therapeutic Players - Biogen, Sarepta Therapeutics, Ionis Pharmaceuticals, & Alnylam Pharmaceuticals

, /PRNewswire/ -- The report has been added to offering.

IONS : 36.68 (-2.94%)
SRPT : 83.14 (-3.46%)
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

BIIB : 396.08 (-2.48%)
REGN : 527.49 (-0.24%)
RHHBY : 47.7700 (+0.23%)
BMY : 67.42 (+0.19%)
AGEN : 5.04 (-1.95%)
SRPT : 83.14 (-3.46%)
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

RHHBY : 47.7700 (+0.23%)
PFE : 39.59 (-0.10%)
SRPT : 83.14 (-3.46%)
SLDB : 4.03 (-1.95%)
Sarepta Therapeutics (SRPT) Moves 8.4% Higher: Will This Strength Last?

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase...

SRPT : 83.14 (-3.46%)
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday

Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.

SRPT : 83.14 (-3.46%)
Walmart, Sarepta rise; Chevron, D.R. Horton fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Tuesday:

WMT : 140.00 (-0.40%)
TWLO : 335.50 (-2.21%)
SRPT : 83.14 (-3.46%)
CVX : 110.30 (+2.16%)
DHI : 88.66 (+0.77%)
Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive 12-week expression and safety results from the first 11 participants enrolled...

SRPT : 83.14 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

3rd Resistance Point 94.75
2nd Resistance Point 92.37
1st Resistance Point 87.76
Last Price 83.14
1st Support Level 80.77
2nd Support Level 78.39
3rd Support Level 73.78

See More

52-Week High 181.83
Fibonacci 61.8% 138.22
Fibonacci 50% 124.76
Fibonacci 38.2% 111.29
Last Price 83.14
52-Week Low 67.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar